JP2020529193A5 - - Google Patents

Download PDF

Info

Publication number
JP2020529193A5
JP2020529193A5 JP2019571019A JP2019571019A JP2020529193A5 JP 2020529193 A5 JP2020529193 A5 JP 2020529193A5 JP 2019571019 A JP2019571019 A JP 2019571019A JP 2019571019 A JP2019571019 A JP 2019571019A JP 2020529193 A5 JP2020529193 A5 JP 2020529193A5
Authority
JP
Japan
Prior art keywords
dna
amount
subject
threshold
previous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019571019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529193A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/038604 external-priority patent/WO2018237078A1/en
Publication of JP2020529193A publication Critical patent/JP2020529193A/ja
Publication of JP2020529193A5 publication Critical patent/JP2020529193A5/ja
Pending legal-status Critical Current

Links

JP2019571019A 2017-06-20 2018-06-20 ドナー特異的セルフリーdnaを用いる移植対象における状態の評価 Pending JP2020529193A (ja)

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
US201762522547P 2017-06-20 2017-06-20
US201762522556P 2017-06-20 2017-06-20
US201762522560P 2017-06-20 2017-06-20
US62/522,547 2017-06-20
US62/522,556 2017-06-20
US62/522,560 2017-06-20
US201762542787P 2017-08-08 2017-08-08
US201762542790P 2017-08-08 2017-08-08
US62/542,790 2017-08-08
US62/542,787 2017-08-08
US201762546872P 2017-08-17 2017-08-17
US201762546798P 2017-08-17 2017-08-17
US201762546848P 2017-08-17 2017-08-17
US62/546,848 2017-08-17
US62/546,798 2017-08-17
US62/546,872 2017-08-17
US201762571715P 2017-10-12 2017-10-12
US201762571709P 2017-10-12 2017-10-12
US62/571,709 2017-10-12
US62/571,715 2017-10-12
US201762576641P 2017-10-24 2017-10-24
US62/576,641 2017-10-24
US201862632960P 2018-02-20 2018-02-20
US62/632,960 2018-02-20
US201862653261P 2018-04-05 2018-04-05
US62/653,261 2018-04-05
PCT/US2018/038604 WO2018237078A1 (en) 2017-06-20 2018-06-20 ASSESSMENT OF CONDITIONS IN GRAFT SUBJECTS USING SPECIFIC ACELLULAR DNA FROM A DONOR

Publications (2)

Publication Number Publication Date
JP2020529193A JP2020529193A (ja) 2020-10-08
JP2020529193A5 true JP2020529193A5 (cg-RX-API-DMAC7.html) 2021-07-29

Family

ID=63047415

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019571019A Pending JP2020529193A (ja) 2017-06-20 2018-06-20 ドナー特異的セルフリーdnaを用いる移植対象における状態の評価

Country Status (8)

Country Link
US (1) US20210139988A1 (cg-RX-API-DMAC7.html)
EP (1) EP3642367B1 (cg-RX-API-DMAC7.html)
JP (1) JP2020529193A (cg-RX-API-DMAC7.html)
CN (1) CN111094593A (cg-RX-API-DMAC7.html)
AU (1) AU2018288835A1 (cg-RX-API-DMAC7.html)
CA (1) CA3067634A1 (cg-RX-API-DMAC7.html)
IL (1) IL271458A (cg-RX-API-DMAC7.html)
WO (1) WO2018237078A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
EP2854058A3 (en) 2010-05-18 2015-10-28 Natera, Inc. Methods for non-invasive pre-natal ploidy calling
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US12655483B2 (en) 2010-05-18 2026-06-16 Natera, Inc. Methods for simultaneous amplification of target loci
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
AU2011348100B2 (en) 2010-12-22 2016-08-25 Natera, Inc. Methods for non-invasive prenatal paternity testing
JP6153874B2 (ja) 2011-02-09 2017-06-28 ナテラ, インコーポレイテッド 非侵襲的出生前倍数性呼び出しのための方法
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
PL3117012T5 (pl) 2014-03-14 2026-03-16 Caredx, Inc. Sposoby monitorowania terapii immunosupresyjnych u biorcy przeszczepu
RU2717641C2 (ru) 2014-04-21 2020-03-24 Натера, Инк. Обнаружение мутаций и плоидности в хромосомных сегментах
US20180173845A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
EP4428863A3 (en) 2015-05-11 2024-12-11 Natera, Inc. Methods and compositions for determining ploidy
JP7280044B2 (ja) 2016-04-15 2023-05-23 ナテラ, インコーポレイテッド 肺癌の検出方法
WO2018067517A1 (en) 2016-10-04 2018-04-12 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
CN110945136A (zh) 2017-06-20 2020-03-31 威斯康星州立大学医学院 使用总无细胞dna评估移植并发症风险
WO2019118926A1 (en) 2017-12-14 2019-06-20 Tai Diagnostics, Inc. Assessing graft suitability for transplantation
EP3737773B1 (en) 2018-01-12 2023-04-12 Natera, Inc. Novel primers and uses thereof
DK3781714T3 (da) 2018-04-14 2026-03-30 Natera Inc Fremgangsmåder til cancerpåvisning og -overvågning ved personlig påvisning af cirkulerende tumor-dna
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
WO2020206292A2 (en) * 2019-04-03 2020-10-08 The Medical College Of Wisconsin, Inc. Assessing conditions in transplant subjects using donor-specific cell-free dna
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
US12305235B2 (en) 2019-06-06 2025-05-20 Natera, Inc. Methods for detecting immune cell DNA and monitoring immune system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2496720T3 (da) * 2009-11-06 2020-09-28 Univ Leland Stanford Junior Ikke-invasiv diagnose af transplantatafstødning i organ-transplanterede patienter
US10385396B2 (en) * 2012-04-19 2019-08-20 The Medical College Of Wisconsin, Inc. Highly sensitive surveillance using detection of cell free DNA
CA2922746A1 (en) * 2013-09-06 2015-03-12 Immucor Gti Diagnostics, Inc. Compositions and methods for diagnosis and prediction of solid organ graft rejection
WO2015058194A1 (en) * 2013-10-18 2015-04-23 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Allele specific pcr assay for detection of nucleotide variants
WO2015069933A1 (en) * 2013-11-06 2015-05-14 The Board Of Trustees Of The Leland Stanford Junior University Circulating cell-free dna for diagnosis of transplant rejection
WO2016123698A1 (en) * 2015-02-06 2016-08-11 Uti Limited Partnership Diagnostic assay for post-transplant assessment of potential rejection of donor organs
AU2016255573A1 (en) * 2015-04-30 2017-12-21 The Medical College Of Wisconsin, Inc. Multiplexed optimized mismatch amplification (MOMA)-real time PCR for assessing cell-free DNA

Similar Documents

Publication Publication Date Title
JP2020524519A5 (cg-RX-API-DMAC7.html)
Iwai et al. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes
Azakie et al. Improving outcomes of the Fontan operation in children with atrial isomerism and heterotaxy syndromes
Kiamanesh et al. The state of the heart biopsy: a clinical review
JP2020529193A (ja) ドナー特異的セルフリーdnaを用いる移植対象における状態の評価
van SUYLEN et al. The DD genotype of the angiotensin converting enzyme gene is negatively associated with right ventricular hypertrophy in male patients with chronic obstructive pulmonary disease
Theuerle et al. Utility of the ACC/AHA lesion classification as a predictor of procedural, 30‐day and 12‐month outcomes in the contemporary percutaneous coronary intervention era
Daud et al. Microvascular loss and diastolic dysfunction in severe symptomatic cardiac allograft vasculopathy
Olivieri et al. Homozygosity for angiotensinogen 235T variant increases the risk of myocardial infarction in patients with multi-vessel coronary artery disease
Clausen et al. Droplet digital PCR-based testing for donor-derived cell-free DNA in transplanted patients as noninvasive marker of allograft health: Methodological aspects
Beller et al. Does preoperative troponin level impact outcomes after coronary artery bypass grafting?
Kanamori et al. Noninvasive graft monitoring using donor‐derived cell‐free DNA in Japanese liver transplantation
Chopra et al. Emerging role of cell-free DNA in kidney transplantation
Grauhan et al. Donor-transmitted coronary atherosclerosis
Richmond et al. Validation of donor fraction cell-free DNA with biopsy-proven cardiac allograft rejection in children and adults
Brown et al. Impact of Mon2 monocyte‐platelet aggregates on human coronary artery disease
Deshpande et al. Evaluating threshold for donor fraction cell‐free DNA using clinically available assay for rejection in pediatric and adult heart transplantation
Bonnet et al. Sudden cardiac death after heart transplantation: a population-based study
Mehra et al. Clinical implications and longitudinal alteration of peripheral blood transcriptional signals indicative of future cardiac allograft rejection
Harskamp et al. Impact of extracardiac vascular disease on vein graft failure and outcomes after coronary artery bypass surgery
Böhmer et al. Absolute quantification of donor-derived cell-free DNA following pediatric and adult heart transplantation
Pradhan et al. Telomere length is associated with adverse atrial remodeling in patients with atrial fibrillation
Cho et al. Quilty lesions in the endomyocardial biopsies after heart transplantation
Doucet et al. Outcomes of left main revascularization in patients with acute coronary syndromes and stable ischemic heart disease: analysis from the EXCEL trial
Bahniwal et al. Diagnostic approach to elevated dd-cfDNA with reassuring EMB in heart transplantation